S
096530
vs
K
KOSPI 200
Over the past 12 months, Seegene Inc has underperformed KOSPI 200, delivering a return of +24% compared to KOSPI 200's +142% growth.
Stocks Performance
096530 vs KOSPI 200
Performance Gap
096530 vs KOSPI 200
Performance By Year
096530 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Seegene Inc
Glance View
Seegene Inc. makes molecular diagnostic tests used to detect infectious diseases and other medical conditions from patient samples. Its core products are test kits, instruments, and software that labs use to run PCR-based testing and interpret results. The company focuses on the technology that lets one sample be tested for many targets at once, which helps laboratories identify the exact cause of an infection more quickly and efficiently. Its main customers are hospitals, clinical laboratories, public health labs, and diagnostic distributors in Korea and overseas. Seegene usually earns money by selling test kits and related consumables, along with testing instruments and software tools that support the workflow. Because diagnostic labs need recurring supplies to keep testing, the business is tied to ongoing use rather than one-time sales alone. What makes Seegene different is that it sits in the middle of the molecular diagnostics value chain as a developer of both assay chemistry and testing workflows, not just a maker of generic lab equipment. It builds tests for specific pathogens and conditions, then packages them with systems that help labs run large test menus on common PCR machines. That gives the company a role as a specialized supplier to labs that want accurate, automated testing with less manual work.
